$21.56
-1.7%Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Capital-intensive growth: Heavy reinvestment limits current cash available but may drive future returns. Assess whether CapEx supports compelling growth opportunities with adequate ROI.
ENOV โข NYSE
| Enovis Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-1.2B | -824.8M | -33.3M | -11.8M | 76.3M | 45.8M | -517.1M | 154.5M | 169.5M | 145.2M | 187.2M | 420.3M | 209.1M | -42.3M | 4.6M | 16.2M | 21.7M | -571K | 64.9M | 94K | |
294.4M | 284.8M | 217.1M | 219.7M | 262.9M | 246.2M | 236M | 141.9M | 134.8M | 143.3M | 154.5M | 174.7M | 119.3M | 200.4M | 22.6M | 16.1M | 15.1M | 14.8M | 16.9M | 13.1M | |
-2.2M | -10M | -27.4M | 6.3M | -22.2M | -29.2M | -590K | -66.6M | 12.1M | -1.7M | -22.7M | -139.5M | 9.9M | 7.2M | -1.7M | -296K | 3.6M | -13.4M | 22.2M | -6.2M | |
32.9M | 29.7M | 34.1M | 39M | 35.4M | 28.9M | 22M | 25.1M | 21.5M | 19M | 16.3M | 17.6M | 13.3M | 9.4M | 4.9M | 3.1M | 2.6M | 11.3M | 0.0 | 0.0 | |
1.1B | 647.8M | -28.2M | -88.6M | 20.8M | 5.2M | 522.2M | 4.8M | -87M | 4.2M | 10.1M | 9.1M | 30.6M | 68.7M | 22.6M | -518K | 613K | -16M | -35K | 1M | |
(0.0) | (10.8M) | (12.5M) | (31.4M) | (47.2M) | (59.4M) | (134.9M) | (97.5M) | (70.7M) | (77.1M) | (79.5M) | (82.7M) | (93.9M) | (70.7M) | -16.7M | (5.8M) | (16.6M) | (18.5M) | (0.0) | (0.0) | |
15.5M | -13.9M | -27.3M | -220.5M | -17.1M | 5M | -131.5M | -33.3M | -32.1M | -63M | -41.6M | -96.4M | -20.1M | -10.4M | 4.3M | 27.3M | -5.3M | -27.7M | -29.4M | -25.4M | |
217.3M | 113.5M | 135M | -55.9M | 356.1M | 301.9M | 130.9M | 226.4M | 218.8M | 247M | 303.8M | 385.8M | 362.2M | 164.3M | 57.2M | 62M | 38.3M | -31.5M | 74.5M | -17.4M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-197.4M | -180.7M | -122.2M | -105.5M | -104.2M | -114.8M | -125.4M | -69.6M | -68.8M | -63.3M | -69.9M | -81.3M | -71.5M | -83.6M | -14.8M | -12.5M | -11M | -20.1M | -13.7M | -10.2M | |
(16.4M) | -769.9M | -152.8M | -73.7M | -223.3M | -69.8M | -1.5B | -272.5M | (143.5M) | -26M | -196M | -948.8M | -372.5M | -1.9B | -56.3M | -28M | -1.3M | -439K | -33M | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 139.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.6M | -4.8M | 32.6M | 2.7M | 7M | 9.6M | 7.8M | 34.8M | 15.1M | 7.2M | 18.9M | 3.1M | -31M | 2.3M | 1.2M | 74K | 219K | 23K | 133K | 157K | |
-179.4M | -955.5M | -242.5M | -176.4M | -320.5M | -175.1M | -1.6B | -167.9M | (89.9M) | -82M | -247M | -1B | -475M | -1.9B | -70M | -40.4M | -12M | -20.5M | -46.5M | -10.1M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
1.3M | -2.9M | 1.8M | 5.8M | 745.2M | 3.5M | 11.9M | -195.3M | 6.9M | -18.6M | -21.3M | 613.9M | 324.2M | 756.8M | 3.7M | 912K | 0.0 | 187.3M | 0.0 | 0.0 | |
-43.6M | 859.2M | 217.2M | -1.6B | -150.4M | -118.3M | 1.1B | 158.2M | -277.4M | -118.8M | -88.9M | 90.9M | -309M | 1.1B | 29M | -9M | -5.4M | -113.9M | 11.7M | 26.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.9M | -20.4M | -17.4M | (0.0) | (0.0) | -38.5B | -38.5M | (0.0) | (0.0) | |
(0.0) | -4.8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -200M | (0.0) | -20.8M | -27.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -5.7B | -5.7M | (0.0) | (0.0) | |
-10.1M | -9.5M | -91.2M | 1.1B | -9.9M | -16.8M | 248.8M | -5.4M | -10M | -5.6M | -15M | -31.4M | -39.8M | -29.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-52.4M | 846.8M | 127.8M | -465.1M | 584.9M | -131.7M | 1.4B | -47.2M | -280.4M | -145.2M | -131.3M | 650M | -45.1M | 2.2B | 32.7M | -8M | -5.4M | 34.8M | 11.7M | 26.6M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
2.7M | -1.5M | 219K | 2.3M | -2.2M | -3.8M | -3.1M | -28.4M | 12.1M | 4.5M | -33.6M | -11.5M | -13.3M | -8.9M | -5.4M | -2.9M | 379K | -2.1M | 790K | 660K | |
-11.8M | 3.3M | 20.5M | -695.1M | 618.3M | -8.6M | -135.4M | -17M | 40.3M | 24.3M | -108M | -5.9M | -171.1M | 407.3M | 14.6M | 10.6M | 21.2M | -19.3M | 40.5M | -213K | |
48.2M | 44.8M | 24.3M | 719.4M | 101.1M | 109.6M | 245M | 262M | 221.7M | 197.5M | 305.4M | 311.3M | 482.4M | 75.1M | 60.5M | 50M | 28.8M | 48.1M | 7.6M | 7.8M | |
36.4M | 48.2M | 44.8M | 24.3M | 719.4M | 101.1M | 109.6M | 245M | 262M | 221.7M | 197.5M | 305.4M | 311.3M | 482.4M | 75.1M | 60.5M | 50M | 28.8M | 48.1M | 7.6M | |
19.9M | -67.2M | 12.8M | -161.3M | 251.9M | 187.2M | 5.5M | 156.7M | 150M | 183.7M | 233.9M | 304.4M | 290.7M | 80.7M | 42.4M | 49.4M | 27.3M | -51.6M | 60.8M | -27.6M |
ENOV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q2 Q2 | May 07, 2026 | April 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 10, 2025 | December 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 07, 2025 | 2025 |
Continue your ENOV research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.